LLY vs ORCL: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and Oracle Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
Oracle Corporation · Technology
$149.12
+45.0% upside to fair value
Med Conviction
Grade B
High Quality
QuantHub Verdict
ORCL has more upside to fair value
(+45.0%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
ORCL |
| Current Price |
$1,183.72 |
$149.12 |
| Fair Value Estimate |
$1,208.00 |
$216.22 |
| Upside to Fair Value |
+2.1%
|
+45.0%
|
| Market Cap |
$1,114.8B |
$429.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.8x
|
14.6x
|
| Price / Sales |
14.0x
|
6.0x
|
| Price / FCF |
52.7x
|
—
|
| Revenue Growth YoY |
+47.7%
|
+29.6%
|
| Gross Margin |
83.4%
|
63.9%
|
| Operating Margin |
49.7%
|
32.4%
|
| Return on Equity |
92.6%
|
42.6%
|
| Dividend Yield |
0.57% |
1.34% |
| FCF Yield |
1.9%
|
—
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
Oracle is a global enterprise software and cloud infrastructure provider whose portfolio spans the Oracle Database, Java, Fusion Cloud SaaS applications (ERP, EPM, SCM, HCM), NetSuite, and Oracle Cloud Infrastructure, sold through a direct sales force to businesses, governments, and educational institutions worldwide. The business quality is high on fundamentals: trailing-twelve-month gross margi…
Accumulation Zones
| Metric |
LLY |
ORCL |
| Zone Low |
$906.00 |
$162.16 |
| Zone High |
$1,026.80 |
$183.79 |
| In Buy Zone? |
No
|
Yes
|